REVITALIZE (Ovarian Cancer) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to test a telehealth intervention that is designed to help women who are suffering from fatigue while taking parp inhibitors for their ovarian cancer. We want to know how well it works compared to current, standard clinical methods.
Cáncer de ovario
¿Quién puede participar en el Estudio?
Adults ages 18+ who:
- Are diagnosed with ovarian, fallopian tube, or primary peritoneal cancer
- Have completed surgery and chemotherapy
- Have been taking a parp inhibitor for at least 2 months
- English speaking
- Have a high level of fatigue
For more information, contact the study team at amelia.lorenzo@duke.edu.
¿Qué Implica?
Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) a 1 de 2 grupos:
- The telehealth intervention group; OR
- The standard-of-care group
If you are assigned to the telehealth group, you will participate in a series of telehealth sessions designed to reduce the effects of fatigue. There will be 10 sessions over the course of 6 months.
If you are assigned to the standard-of-care group, you will receive informational print outs about managing fatigue and other side effects of parp inhibitors.
Detalles del Estudio
